Clinical Trial Update: Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old [Phase 1]

View source ↗

Summary

Phase 1 safety update of HIV vaccine 732462 in HIV-infected adults aged 18 to 55. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome

Drugs mentioned

• HIV Vaccine 732462

Snippet

Sponsor: GlaxoSmithKline | Conditions: AIDS | Phase 1 | Status: COMPLETED